On Sept. 15, 2021, InBios announced that it had received Emergency Use Authorization from the U.S. Food and Drug Administration for its SCoV-2 Detect IgG Rapid Test, a qualitative immunoassay for the detection of IgG antibodies to SARS-CoV-2.

This marked InBios’ fifth EUA granted for SARS-CoV-2 diagnostics since the beginning of the COVID-19 pandemic.